Full-Time
Posted on 6/29/2025
Global provider of medical care products
$68k - $93.5k/yr
No H1B Sponsorship
Highland Park, IL, USA
In Person
Bachelor's
See people who can refer or advise you
Baxter International produces medical products and equipment used in hospitals and blood banks. Its innovations include sterile IV solutions and blood-storage technologies, such as the Transfuso-Vac that extended blood shelf life and a plastic blood storage container. The company differentiates itself through a long history of sterile manufacturing, blood-storage breakthroughs, and strategic acquisitions that expand its product portfolio and scale. Its goal is to provide reliable, safe medical products that support patient care and hospital operations worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Deerfield, Illinois
Founded
1931
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Parental Leave
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Commuter Benefits
Mental Health Support
2 drugs recalled over potential fiberglass, steel presence. by: Zach Kaplan Posted: Aug 27, 2026 / 08:35 PM EDT Updated: Aug 27, 2026 / 08:50 PM EDT (NewsNation) - Baxter International voluntarily recalled two drugs this week over the potential presence of particulate matter, including steel and fiberglass. The Food and Drug Administration said Aug. 25 that the large healthcare company voluntarily recalled a single lot of its 70% Dextrose Injection over the potential presence of steel particles. The product was distributed nationwide to healthcare providers from July 25, 2026, through July 28, 2026. The injection is used to "provide your body with extra water and carbohydrates," according to the Mayo Clinic. "It is used when a patient is not able to drink enough liquids or when additional fluids are needed." The FDA warned that the presence of steel particles in the solution can lead to potentially life-threatening health consequences. The recall is most likely to impact patients who get IV nutrition at home, Medical Daily reported. That same day, the FDA announced a second voluntary recall for Anticoagulant Sodium Citrate Solution because it may contain fiberglass. The product was distributed from July 2, 2026, through July 11, 2026, to one customer in the U.S. The extent of harm that particulate matter can cause in the sodium citrate solution depends on "the size, number, morphology, and composition of the foreign material," the FDA said. The solution slows down blood clotting during apheresis procedures, the agency previously confirmed. Both products were packaged in VIAFLEX plastic containers. As of this week, the FDA said there have been no reports of adverse effects from these products. For questions, consumers can call the company at 888-229-0001 during standard business hours. "Baxter is contacting customers by email with instructions on how to identify and return the impacted product(s)," the FDA added. This follows another voluntary Baxter recall last month for one lot of its Cefazolin in Dextrose Injection after cardboard was found in the solution, the FDA said.
Baxter issues voluntary nationwide recall for one lot of Anticoagulant Sodium Citrate Solution due to potential presence of particulate matter. When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company. Summary. * Company Announcement Date: - August 25, 2026 * FDA Publish Date: - August 25, 2026 * Product Type: - Drugs * Reason for Announcement: - Potential presence of particulate matter identified as fiberglass in the solution * Company Name: - Baxter International Inc. * Brand Name: - Baxter * Product Description: - Anticoagulant Sodium Citrate Solution USP, 250 mL VIAFLEX Plastic Container Company Announcement. FOR IMMEDIATE RELEASE - AUG. 25, 2026 - DEERFIELD, Ill., Baxter International Inc. (NYSE:BAX) is voluntarily recalling one lot of Anticoagulant Sodium Citrate Solution due to the potential presence of particulate matter identified as fiberglass in the solution. Risk Statement: Anticoagulant Sodium Citrate Solution is intended for use with automated apheresis devices. Administration of Anticoagulant Sodium Citrate containing particulate matter may lead to adverse health consequences, the extent and severity of harm depend on the size, number, morphology and composition of the foreign material. In the absence of in-line filtration, these particles may cause local vein irritation, inflammatory or hypersensitivity reactions, and systemic embolization that could result in tissue or organ injury. As of 8/25/2026, Baxter has not received any reports of adverse events related to this issue. The product is intended for use only with apheresis devices. It is not for direct intravenous infusion and the directions for use are contained in the owners operating and maintenance manual of the apheresis machine to be used. The product is packaged in 250 mL VIAFLEX Plastic Containers, with 36 units per case. Additional information can be found in the table below. Affected Product: | Product Code | Product Description | Lot Number | Expiration Date | NDC Number | | 2B7867Q | Anticoagulant Sodium Citrate Solution USP, 250 mL VIAFLEX Plastic Container | Y493475 | 31-Dec-2027 | 0338-9669-01 | The affected lot can be identified by locating the lot number and expiration date on the individual product and shipping carton, as shown in the images below. The impacted product was distributed from 7/2/2026 to 7/11/2026 to one customer in the United States. The customer should immediately discontinue use of and return all affected units in accordance with their facility's process. Baxter is contacting the customer by email with instructions on how to identify and return the impacted product. For general questions regarding this communication, please contact Baxter Healthcare Center for Service at 888-229-0001 between the hours of 7:00 am and 6:00 pm Central Time, Monday through Friday. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. * Complete and submit the report Online: www.fda.gov/medwatch/report.htm * Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm[2] or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 The United States Food and Drug Administration (FDA) has been notified of this action. Company contact information. * Consumers: - Baxter Healthcare Center - 888-229-0001 * Media: - Brenna Byrne - (224) 948-5353 - [email protected]
Baxter taps Smith+Nephew CFO John Rogers as finance chief. He succeeds interim Baxter CFO Anita Zielinski, who is resigning to become the chief accounting officer of Cardinal Health. August 19, 2026 Associate Editor Baxter revealed that it has appointed Smith+Nephew chief financial officer (CFO) John Rogers in order to become its new finance chief. He will take office on October 1. Rogers has headed finance operations at Smith+Nephew since 2024 after beginning with the orthopedics company as CFO-designate in 2023. Before that, he was CFO of WPP plc, J Sainsbury plc, and CEO of Argos, Habitat and Sainsbury's clothing and general merchandise businesses. He also has public-company board experience, including as an independent director and audit committee chair at Grab Holdings and previously Travis Perkins. On September 29, Rogers relocated from the UK to the U.S. for convenience and support of Smith+Nephew's largest market. He succeeds interim CFO Anita Zielinski, who announced plans resign in order to become the chief accounting officer of Cardinal Health earlier this week. President and CEO Andrew Hider: "John is a proven global finance executive with extensive operational expertise and a successful track record leading complex transformation initiatives. He is an ideal fit for Baxter as we continue to stabilize the business, strengthen our balance sheet and drive a culture of continuous improvement. I am confident John will help us build on this work, sharpen our execution and create sustainable value for our customers, employees, investors and other Baxter stakeholders." Rogers: "I am honored to join Baxter, a company with a nearly century-long history, a powerful Mission to Save and Sustain Lives and an essential role across healthcare. Baxter's focus on continuous improvement, strengthening its balance sheet and driving enhanced performance is closely aligned with my experience leading global finance organizations and supporting large-scale business transformation. I look forward to working with Andrew, the Finance team and my new colleagues across Baxter to create long-term value for all stakeholders."
Baxter's interim CFO Anita Zielinski departs for Cardinal Health. Zielinski leaves Baxter after less than two years with the company to become Cardinal Health's chief accounting officer. August 17, 2026 Associate Editor Baxter's interim chief financial officer (CFO) and senior VP, chief accounting officer and controller Anita Zielinski will resign on September 15 in order to become the chief accounting officer of Cardinal Health, according to SEC filings issued by both companies. Zielinski spent under two years at Baxter, becoming interim CFO in March following Joel Grade's departure from the company in order to prioritize family matters. Before joining Baxter, she worked at Sysco Corporation, where she was most recently senior VP and CFO of U.S. Foodservice Operations, the company's largest business segment. Before Sysco, Zielinski spent over two decades at Ernst & Young, including as an audit partner. She succeeds Mary Scherer, who will support Zielinski in her role as chief accounting officer through November 5. Zielinski will begin her work at Cardinal Health on September 16. According to Cardinal Health's SEC filing, Ms. Zielinski will receive a $750,000 signing bonus and $1 million in restricted stock units vesting over three years, primarily to offset compensation forfeited from her former employer. This announcement follows Baxter's recently released Q2 earnings report. The Deerfield, Illinois-based company pocketed $2.96 billion of sales in Q2, growing 5% on a reported and organic basis. Baxter also updated its segment reporting structure beginning in Q2 to consist of businesses Medical Products & Therapies and Healthcare Systems & Technologies. The former rose 7% in Q2 with $2.1 billion of sales, and the latter grew 4% to $801 million.
Zoetis names Saccaro CFO, chief operating officer. The basics: * Saccaro will join Zoetis as CFO, COO Aug. 17 * Newly created role includes oversight of manufacturing, supply operations * Current CFO will serve as special advisor to the CEO through early 2027 * Zoetis reported $2.5B in Q2 2026 revenue Zoetis Inc. has appointed James (Jay) Saccaro as executive vice president, chief financial officer and chief operating officer, effective Aug. 17, 2026. The Parsippany-headquartered animal health company announced the new hire Aug. 6. Zoetis also said it's a newly created position. Saccaro will take over responsibilities from Wetteny Joseph, who will remain with the company as a special advisor to CEO Kristin Peck until early 2027. According to Zoetis' executive team page, Joseph's title is executive vice president and CFO. Saccaro joins Zoetis from GE HealthCare, where he most recently served as vice president and CFO. At that company, Saccaro led initiatives across sectors such as finance, accounting, new product planning, R&D prioritization and capital allocation, according to Zoetis. Prior to GE HealthCare, Saccaro held various financial leadership positions at Baxter International Inc., Hillrom, Clear Channel Communications and The Walt Disney Co., according to his LinkedIn profile. New position. "We are excited to welcome Jay to Zoetis as we prepare for our next wave of innovation-driven growth," Peck said in a statement. "Jay brings a unique combination of skills to this newly created leadership position. He is a seasoned finance executive with 12 years of CFO experience at some of the world's leading healthcare companies and has proven expertise in successfully developing and executing company-wide strategic initiatives." Peck added that responsibilities of the expanded position will include: * Strengthening the company's global manufacturing and supply operations * Enhancing supply chain and distribution performance * Driving greater operational agility Saccaro said he was "thrilled to join the world's leading animal health company," adding that there was "tremendous runway to build on" Zoetis' legacy. "From the company's deep innovation pipeline to its products that have built and defined categories in the industry, Zoetis is an exceptional business grounded in a deep commitment to setting new standards for the future of animal care." 'A challenging quarter' Peck also thanked Joseph "for his strong leadership, partnership, and many important contributions since joining the company five years ago." In his final earnings update posted on LinkedIn Aug. 6, Joseph said, "I want to recognize our colleagues, who remained focused on delivering for our customers despite a challenging quarter." In the video, Joseph noted that "results this quarter fell short of our expectations," adding that, on an organic operational basis, Zoetis' revenue declined 1% and adjusted net income declined 2%. The company's quarterly report noted revenue of $2.5 billion for the second quarter of 2026. Breaking down results across its U.S. and international segments: * U.S. segment revenue: $1.3 billion, decreasing 7% relative to Q2 2025 * International segment revenue: $1.2 billion, increasing 8% on a reported basis and 6% on an organic operational basis compared with Q2 2025 Joseph said challenges such as declining veterinary visits and greater pet owner price sensitivity placed pressure on the companion animal industry. However, he said the company was "responding with urgency and focus." He added on the post, "I close this chapter with confidence in Zoetis' people, portfolio and pipeline. The work ahead is clear, and the company has the talent and capabilities to execute and create long-term value."